Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register
oleh: Emilia Antonucci MSc, Ludovica Migliaccio MTc, Maria Abbattista MD, Antonella Caronna MD, Sergio De Marchi MD, Angela Di Giorgio MD, Rosella Di Giulio MD, Teresa Lerede MD, Maria Grazia Garzia MD, Ida Martinelli MD, Daniela Mastroiacovo MD, Marco Marzolo MD, Elisa Montevecchi MD, Daniele Pastori MD, Pasquale Pignatelli MD, Daniela Poli MD, Luigi Ria MD, Angelo Santoliquido MD, Sophie Testa MD, Gualtiero Palareti MD
| Format: | Article |
|---|---|
| Diterbitkan: | SAGE Publishing 2020-10-01 |
Deskripsi
Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report, 472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients. Anticoagulant treatment lasted ≥3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis because considered at high risk of recurrence or had thrombophilic abnormalities. d -dimer testing, assessment of residual thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient.